Cancer Center

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 88%
3. Melanoma 63%
4. Prostatic Neoplasms 61%
5. Prostate 57%
6. Drug Therapy 51%
7. 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one 49%
8. Survival 49%
9. Cyclophosphamide 48%
10. Doxorubicin 47%
11. Therapeutics 45%
12. Adenoma 39%
13. Non-Small Cell Lung Carcinoma 39%
14. Carcinoma 38%
15. Cell Line 36%
16. Cisplatin 34%
17. Small Cell Lung Carcinoma 32%
18. In Vitro Techniques 31%
19. Pharmacokinetics 29%
20. Bone Marrow Transplantation 28%
21. Pharmaceutical Preparations 27%
22. Neoplasm Metastasis 27%
23. Skin 26%
24. Recurrence 26%
25. Bone Marrow 26%
26. Etoposide 25%
27. Placebos 25%
28. Prostate-Specific Antigen 24%
29. Leukemia 24%
30. Integrins 23%
31. Contrast Media 23%
32. Acute Myeloid Leukemia 23%
33. Lymphocytes 21%
34. Colorectal Neoplasms 21%
35. Serum 20%
36. Selenium 20%
37. Radiotherapy 19%
38. Progression-Free Survival 19%
39. Microbubbles 19%
40. Mitomycin 18%
41. Genes 18%
42. Matrix Metalloproteinase 7 18%
43. Acquired Immunodeficiency Syndrome 18%
44. Confidence Intervals 18%
45. Proteins 18%
46. Colonic Neoplasms 18%
47. Apoptosis 17%
48. Liposomes 17%
49. Keratins 17%
50. Antibodies 17%
51. Biopsy 17%
52. Polyps 17%
53. Busulfan 17%
54. Clinical Trials 16%
55. Bone and Bones 16%
56. Liver 16%
57. Kidney 16%
58. promatrilysin 16%
59. Vincristine 16%
60. Immunotherapy 16%
61. Chemoprevention 16%
62. Multiple Myeloma 16%
63. Growth 16%
64. Paclitaxel 15%
65. Interferons 15%
66. kalinin 15%
67. Transplants 15%
68. Cell Transplantation 15%
69. Tamoxifen 15%
70. Disease-Free Survival 15%
71. Tea 15%
72. Magnetic Resonance Imaging 15%
73. Adenocarcinoma 15%
74. Combination Drug Therapy 15%
75. Prostatic Intraepithelial Neoplasia 14%
76. Sexual and Gender Minorities 14%
77. Pancreatic Neoplasms 14%
78. Monoclonal Antibodies 14%
79. Dacarbazine 14%
80. DNA 14%
81. Injections 13%
82. Autologous Transplantation 13%
83. Fluorouracil 13%
84. Sarcoma 13%
85. Denosumab 13%
86. T-Lymphocytes 13%
87. Enzymes 12%
88. Interleukin-2 12%
89. Antigens 12%
90. Appointments and Schedules 12%
91. Tumor Necrosis Factor-alpha 12%
92. Ipilimumab 12%
93. Docetaxel 12%
94. Breast 12%
95. Vinorelbine 12%
96. Lymphoma 12%
97. Safety 12%
98. Mycobacterium bovis 12%
99. perfluoropentane 12%
100. Epithelial Cells 12%